Form 4: Mirum Pharma COO Sells Shares for Tax Obligations

Mirum Pharmaceuticals' President and COO, Peter Radovich, sold 2,631 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Peter Radovich, President and COO of Mirum Pharmaceuticals, Inc. (MIRM), reported a transaction on February 2, 2026.
• The transaction involved the sale of 2,631 shares of Mirum Pharmaceuticals Common Stock.
• The shares were sold at a price of $103.3035 per share.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Peter Radovich beneficially owns 20,655 shares of Common Stock directly.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is non-discretionary, solely for tax purposes related to equity compensation, and does not reflect a change in the executive's confidence in the company's future prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that this is a routine insider transaction, specifically a non-discretionary sale to cover tax obligations arising from the vesting of restricted stock units. Such transactions are common for executives receiving equity compensation and are often pre-scheduled under Rule 10b5-1 plans to avoid accusations of trading on inside information.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes and does not signal a change in the executive's view of the company's value.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The transaction reported is a routine, non-discretionary sale by an executive to cover tax obligations associated with the vesting of restricted stock units. This type of insider activity does not typically indicate a change in the company's fundamental outlook or the executive's confidence, thus providing no new information to warrant a change from a 'hold' recommendation.

Keywords

Mirum Pharmaceuticals, MIRM, Form 4, Insider Transaction, Stock Sale, Executive Compensation, Restricted Stock Units, Peter Radovich, Tax Withholding